DK2239269T3 - Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører - Google Patents

Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører

Info

Publication number
DK2239269T3
DK2239269T3 DK10171553.0T DK10171553T DK2239269T3 DK 2239269 T3 DK2239269 T3 DK 2239269T3 DK 10171553 T DK10171553 T DK 10171553T DK 2239269 T3 DK2239269 T3 DK 2239269T3
Authority
DK
Denmark
Prior art keywords
molecular weight
weight markers
copolymer
copolymers
glatiramer acetate
Prior art date
Application number
DK10171553.0T
Other languages
English (en)
Inventor
Alexander Gad
Dora Lis
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22285926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2239269(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK2239269T3 publication Critical patent/DK2239269T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
DK10171553.0T 1998-09-25 1999-09-24 Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører DK2239269T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10169398P 1998-09-25 1998-09-25
EP09004306A EP2090583B1 (en) 1998-09-25 1999-09-24 Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use

Publications (1)

Publication Number Publication Date
DK2239269T3 true DK2239269T3 (da) 2013-04-29

Family

ID=22285926

Family Applications (3)

Application Number Title Priority Date Filing Date
DK09004306.8T DK2090583T3 (da) 1998-09-25 1999-09-24 Copolymer 1-relaterede polypeptider til anvendelse som molekylvægtsmarkører og til terapeutisk anvendelse
DK99949923T DK1115743T3 (da) 1998-09-25 1999-09-24 Copolymer 1-relaterede polypeptider til anvendelse som molekylvægtmarkörer og til terapeutisk anvendelse
DK10171553.0T DK2239269T3 (da) 1998-09-25 1999-09-24 Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK09004306.8T DK2090583T3 (da) 1998-09-25 1999-09-24 Copolymer 1-relaterede polypeptider til anvendelse som molekylvægtsmarkører og til terapeutisk anvendelse
DK99949923T DK1115743T3 (da) 1998-09-25 1999-09-24 Copolymer 1-relaterede polypeptider til anvendelse som molekylvægtmarkörer og til terapeutisk anvendelse

Country Status (18)

Country Link
EP (3) EP1115743B1 (da)
JP (2) JP4629229B2 (da)
AT (2) ATE431359T1 (da)
AU (1) AU757413B2 (da)
CA (2) CA2343929C (da)
CY (3) CY1110490T1 (da)
DE (2) DE69940888D1 (da)
DK (3) DK2090583T3 (da)
ES (3) ES2327301T3 (da)
HK (3) HK1040521A1 (da)
HU (3) HU229719B1 (da)
IL (4) IL142116A0 (da)
NO (2) NO329877B1 (da)
NZ (1) NZ511020A (da)
PT (3) PT2090583E (da)
SI (1) SI1115743T1 (da)
WO (1) WO2000018794A1 (da)
ZA (1) ZA200102269B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
WO2000005250A1 (en) 1998-07-23 2000-02-03 Yeda Research And Development Co., Ltd Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ZA200206457B (en) 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2001097785A2 (en) * 2000-06-20 2001-12-27 Caprion Pharmaceuticals Inc. Basic copolymers for the treatment of prion-related-disease
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
US20040037828A1 (en) * 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
CA2462459C (en) * 2001-10-03 2007-12-18 Jack L. Strominger Copolymers for suppression of autoimmune diseases, and methods of use
US7429374B2 (en) 2001-12-04 2008-09-30 Teva Pharmaceutical Industries, Ltd. Process for the measurement of the potency of glatiramer acetate
US8008258B2 (en) 2003-01-21 2011-08-30 Yeda Research And Development Co. Ltd. Cop 1 for treatment of inflammatory bowel diseases
RU2358753C2 (ru) 2003-08-07 2009-06-20 Хилор Лтд. Фармацевтические композиции и способы для ускорения заживления ран
MXPA06010043A (es) * 2004-03-01 2007-03-07 Peptimmune Inc Metodos y composiciones para el tratamiento de enfermedades autoinmunologicas.
US7655221B2 (en) 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
SI1797109T1 (sl) 2004-09-09 2016-07-29 Yeda Research And Development Co., Ltd. Zmesi polipeptidov, sestavki, ki jih vsebujejo, in postopki za njihovo pripravo ter njihove uporabe
US7858337B2 (en) 2007-03-08 2010-12-28 Novartis Ag Process for the manufacture of a composite material
KR20170123354A (ko) 2009-08-20 2017-11-07 에다 리서치 앤드 디벨럽먼트 컴퍼니 리미티드 글라티라머 아세테이트를 포함하는 약제
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
JP2013541010A (ja) 2010-10-11 2013-11-07 テバ ファーマシューティカル インダストリーズ リミティド グラチラマーアセテートに対する臨床的な反応の予測可能なバイオマーカーとしてのサイトカインバイオマーカー
CA2827275A1 (en) 2011-02-14 2012-09-20 Usv Limited Copolymer-1, process for preparation and analytical methods thereof
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
TW201420111A (zh) 2012-10-10 2014-06-01 Teva Pharma 對格拉默醋酸鹽（ｇｌａｔｉｒａｍｅｒ ａｃｅｔａｔｅ）之臨床反應具預測性之生物標記
CN104098655B (zh) * 2013-04-09 2018-01-30 深圳翰宇药业股份有限公司 用于合成醋酸格拉替雷的质谱内标的多肽
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105218646B (zh) * 2014-06-24 2018-09-21 深圳翰宇药业股份有限公司 一种用于检测醋酸格拉替雷样本的uplc方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
EP3603764B1 (en) * 2015-04-28 2022-03-30 Hybio Pharmaceutical Co., Ltd. High performance liquid chromatography method for polypeptide mixtures
ES2744179T3 (es) 2015-09-24 2020-02-24 Chemi Spa Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2009996A1 (en) * 1989-02-17 1990-08-17 Kathleen S. Cook Process for making genes encoding random polymers of amino acids
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers

Also Published As

Publication number Publication date
HU229289B1 (en) 2013-10-28
DE09004306T1 (de) 2010-12-09
IL209189A (en) 2017-11-30
EP2239269A1 (en) 2010-10-13
CY1112197T1 (el) 2015-12-09
EP2239269B1 (en) 2013-01-16
CA2794705A1 (en) 2000-04-06
EP1115743A1 (en) 2001-07-18
IL209190A0 (en) 2011-01-31
JP4629229B2 (ja) 2011-02-09
CY1110490T1 (el) 2015-04-29
ATE516297T1 (de) 2011-07-15
EP2090583B1 (en) 2011-07-13
AU757413B2 (en) 2003-02-20
IL209189A0 (en) 2011-01-31
CA2343929C (en) 2013-01-29
ATE431359T1 (de) 2009-05-15
SI1115743T1 (sl) 2010-01-29
NZ511020A (en) 2003-06-30
AU6269599A (en) 2000-04-17
PT2239269E (pt) 2013-04-09
CA2794705C (en) 2017-07-18
HU229720B1 (en) 2014-05-28
IL142116A (en) 2010-12-30
PT2090583E (pt) 2011-09-14
WO2000018794A1 (en) 2000-04-06
CA2343929A1 (en) 2000-04-06
CY1113932T1 (el) 2016-07-27
JP2010271325A (ja) 2010-12-02
NO20011441D0 (no) 2001-03-21
HK1040521A1 (en) 2002-06-14
HU229719B1 (en) 2014-05-28
DK2090583T3 (da) 2011-09-12
NO20011441L (no) 2001-05-25
ES2327301T3 (es) 2009-10-27
ZA200102269B (en) 2002-03-19
ES2408706T3 (es) 2013-06-21
IL142116A0 (en) 2002-03-10
EP1115743B1 (en) 2009-05-13
JP2002525378A (ja) 2002-08-13
DE69940888D1 (de) 2009-06-25
PT1115743E (pt) 2009-07-07
HK1133021A1 (en) 2010-03-12
HUP0103889A2 (hu) 2002-03-28
EP1115743A4 (en) 2005-04-27
EP2090583A1 (en) 2009-08-19
NO336685B1 (no) 2015-10-19
NO20100442L (no) 2001-05-25
HK1149279A1 (en) 2011-09-30
IL209190A (en) 2017-11-30
DK1115743T3 (da) 2009-07-27
ES2369642T3 (es) 2011-12-02
NO329877B1 (no) 2011-01-17
HUP0103889A3 (en) 2004-03-01
JP4903886B2 (ja) 2012-03-28

Similar Documents

Publication Publication Date Title
DK2239269T3 (da) Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører
DE69907137T2 (de) Autoklavierbare pharmazeutische zusammensetzungen mit komplexbildner
DK0762888T3 (da) Copolymer-1 forbedringer i præparater af copolymerer
BR9713486A (pt) Preparações farmacêuticas compreendidas de sais de ácido hialurÈnico com anestésicosm locais.
BR9916896A (pt) Diaril aminas substituìdas com 1-heterociclo
DK1091975T3 (da) Ny cyclosporin med forbedret aktivitetsprofil
DE60007095T2 (de) Calanolide zur hemmung von btk
DK0976722T3 (da) Benzamidin-derivater
ES2139931T3 (es) Adhesivo de contacto de uso medico.
DE50001905D1 (de) Herbizide mittel von nachauflauf-herbiziden zur bodenapplikation
DK1189971T3 (da) Funktionelle poly-alpha-aminosyrederivater der er egnede til modificering af biologisk aktive materialer, samt anvendelse deraf
BR0010317A (pt) Bandeja de armazenagem para refrigerador
DK1272652T3 (da) Herpesvirus til immunmodulation
FR2701520B1 (fr) Dispositif de fixation notamment de tablettes, d'étagères ou autres.
TR199900555T2 (xx) Vir�slerin v�cuda yeniden yerle�mesini �nleyici madde olarak proteinerin kullan�m�.
DE29820948U1 (de) Regal zur Aufbewahrung von CD's, CD-ROM's etc.
DK1158050T3 (da) Human cysteinyl-leukotrienreceptor (CysLT2)
DE59408965D1 (de) Verfahren zur Herstellung langzeitstabiler klarer Seren